An Open-Label Study to Evaluate the Penetration of Doripenem in Cerebrospinal Fluid After Doripenem Administration in Pediatric Subjects Less Than 1 Year Chronological Age.

Trial Profile

An Open-Label Study to Evaluate the Penetration of Doripenem in Cerebrospinal Fluid After Doripenem Administration in Pediatric Subjects Less Than 1 Year Chronological Age.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Doripenem (Primary)
  • Indications Bacterial infections; CNS infections
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Dec 2012 Planned End Date changed from 1 May 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 28 Jul 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2011-001114-33).
    • 29 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top